Free tool
FAERS Monitor: Pulmicort Flexhaler
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021949 or its brand name (Pulmicort Flexhaler, Budesonide). Reports on generic versions are filed under their own applications.
Reports
50,377
Serious
35,793
71% of reports
Hospitalization
17,535
Death reported
3,580
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea6,184
- drug ineffective5,799
- off label use5,418
- asthma4,710
- cough3,107
- fatigue2,965
- headache2,761
- condition aggravated2,723
- pneumonia2,606
- diarrhoea2,588
- nausea2,436
- wheezing2,405
- pyrexia2,113
- pain2,097
- malaise2,073
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 527 |
| 2005 | 584 |
| 2006 | 585 |
| 2007 | 775 |
| 2008 | 909 |
| 2009 | 722 |
| 2010 | 1,068 |
| 2011 | 1,577 |
| 2012 | 1,994 |
| 2013 | 1,341 |
| 2014 | 1,610 |
| 2015 | 1,660 |
| 2016 | 1,859 |
| 2017 | 1,985 |
| 2018 | 2,525 |
| 2019 | 3,199 |
| 2020 | 3,777 |
| 2021 | 3,988 |
| 2022 | 4,322 |
| 2023 | 4,241 |
| 2024 | 4,186 |
| 2025 | 4,065 |
| 2026 | 2,875 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,782 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asthmaSignal | 4,710 | 18.1 | 17.6 | 73,358 |
| wheezingSignal | 2,405 | 17.6 | 16.9 | 36,227 |
| coughSignal | 3,107 | 4.7 | 4.5 | 8,967 |
| dyspnoeaSignal | 6,184 | 4.6 | 4.5 | 17,707 |
| condition aggravatedSignal | 2,723 | 3.8 | 3.6 | 5,555 |
| pneumoniaSignal | 2,606 | 3.4 | 3.3 | 4,397 |
| off label useSignal | 5,418 | 2.6 | 2.5 | 5,498 |
| pyrexiaSignal | 2,113 | 2.6 | 2.5 | 2,027 |
| malaise | 2,073 | 2.0 | 1.9 | 1,018 |
| headache | 2,761 | 1.8 | 1.8 | 1,090 |
| drug ineffective | 5,799 | 1.8 | 1.8 | 2,365 |
| diarrhoea | 2,588 | 1.7 | 1.6 | 725 |
| fatigue | 2,965 | 1.6 | 1.5 | 675 |
| pain | 2,097 | 1.4 | 1.4 | 274 |
| nausea | 2,436 | 1.3 | 1.2 | 160 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.